RAPT Therapeutics: A Buy As GSK Acquisition Highlights Long-Acting IgE Candidate

2026-01-20 15:15:45 ET

The last time I spoke about RAPT Therapeutics, Inc. ( RAPT ), it was in a Seeking Alpha article entitled " RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus ." With respect to this article, I primarily noted the development of its CCR4 antagonist zelnecirnon [RPT193] for the treatment of patients with asthma and atopic dermatitis [AD]. The drug was being evaluated to treat these patients in phase 2 clinical testing. The hope was that the FDA clinical hold would end up being lifted from this program....

Read the full article on Seeking Alpha

For further details see: